Correction (DOI:10.1016/j.jaci.2008.09.017);Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 5, 2008, Pages 951-960

  Pauli, Gabrielle ^a   Larsen, Tina H ^b   Rak, Sabina ^c   Horak, Friedrich ^d   Pastorello, Elide ^e   Valenta, Rudolph ^f   Purohit, Ashok ^a   Arvidsson, Monica ^c   Kavina, Alexander ^d   Schroeder, Jan W ^e   Mothes, Nadine ^f   Spitzauer, Susanne ^f   Montagut, Armelle ^g   Galvain, Sylvie ^h   Melac, Michel ^h   André, Claude ^h   Poulsen, Lars K ^b   Malling, Hans Jorgen ^b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Rigshospitalet   (Denmark)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF VIENNA   (Austria)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Delta Consultants   (France)

^h Stallergenes SA   (France)

Author keywords

allergen; allergic rhinitis; allergy; Bet v 1; IgE; IgG4; immunotherapy; Recombinant allergens

Indexed keywords

ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PLACEBO; POLLEN ANTIGEN; POLLEN EXTRACT; PREDNISOLONE;

ADULT; ALLERGIC DISEASE; ANAPHYLAXIS; ARTICLE; BIRCH; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOTHERAPY; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SIDE EFFECT; SKIN SENSITIVITY; SKIN SWELLING; SNEEZING;

EID: 49149107253     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.11.010     Document Type: Erratum

References (33)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1 (1911) 1572-1573
2. Castro A.J., de Dios Alche J., Cuevas J., Romero P.J., Alche V., and Rodriguez-Garcia M.I. Pollen from different olive tree cultivars contains varying amount of the major allergen Ole e 1. Int Arch Immunol 131 (2003) 164-173
3. Gastaminza G., Algorta J., Audicana M., Etxenagusia M., Fernandez E., and Munoz D. Systemic reactions to immunotherapy: influence of composition and manufacturer. Clin Exp Allergy 33 (2003) 470-474
4. Abramson M.J., Puy R.M., and Weiner J.M. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 4 (2003) CD001186
5. Traidl-Hoffmann C., Mariani V., Hochrein H., Karg K., Wagner H., Ring J., et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T-helper type 2 cell polarisation. J Exp Med 201 (2005) 627-636
6. Ng N., Lam D., Paulus P., Batzer G., and Horner A.A. House dust extracts have both TH2 adjuvant and tolerogenic activities. J Allergy Clin Immunol 117 (2006) 1074-1081
7. Moverare R., Elfman L., Vesterinen E., Metso T., and Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP system. Allergy 57 (2002) 423-430
8. van Ree R., Antonicelli L., Akkerdaas J.H., Garritani M.S., Aalberse R.C., and Bonifazi F. Possible induction of food allergy during mite immunotherapy. Allergy 51 (1996) 108-113
9. Van der Veen M.J., Mulder M., Witteman A.M., van Ree R., Aalberse R.C., Jansen H.M., et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. J Allergy Clin Immunol 98 (1996) 1028-1034
10. Trivedi B., Valerio C., and Slater J.E. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 111 (2003) 777-783
11. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2 (2002) 446-453
12. Pauli G., Oster J.P., Deviller P., Heiss H., Bessot J.C., Susani M., et al. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. J Allergy Clin Immunol 97 (1996) 1100-1109
13. Godnic-Cvar J., Susani M., Breiteneder H., Berger A., Havelec L., Waldhör T., et al. Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen. J Allergy Clin Immunol 99 (1997) 354-359
14. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2007. Available at: http://www.ginasthma.com. Accessed October 13, 2008.
15. Bousquet J., Lockey R.F., and Malling H.J. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53 suppl 44 (1998) 1-42
16. Breiteneder H., Pettenburger K., Bito A., Valenta R., Kraft D., Rumpold H., et al. The gene coding for the major birch pollen allergen Bet v 1, is highly homologous to a pea disease resistance response gene. EMBO J 8 (1989) 1935-1938
17. Ferreira F.D., Hoffmann-Sommergruber K., Breiteneder H., Pettenburger K., Ebner C., Sommergruber W., et al. Purification and characterisation of recombinant Bet v 1, the major birch pollen allergen: immunological equivalence to natural Bet v 1. J Biol Chem 268 (1993) 19574-19580
18. Batard T., Didierlaurent A., Chabre H., Mothes N., Bussières L., Bohle B., et al. Characterisation of wild-type recombinant BET v 1a as a candidate vaccine against birch pollen allergy. Int Arch Allergy Immunol 136 (2005) 239-249
19. Mothes-Luksch N., Spitzauer S., Hauswirth A., Krauth M., Valent P., Steiner R., et al. Comparison of in vivo allergenic activity of recombinant Bet v 1 with allergen-specific in vitro immune responses in birch pollen allergic patients. EAACI 2006. XXV Congress of the European Academy of Allergology and Clinical Immunology (2006), European Academy of Allergology and Clinical Immunology, Vienna p. 294
20. Comtois P., and Gagnon L. Concentration pollinique et fréquence des symptômes de pollinose: une méthode pour déterminer les seuils cliniques. Rev Fr Allergol 28 (1988) 279-286
21. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 101 (2004) 14677-14682
22. Stern D.A., Riedler J., Nowak D., Braun-Fachlander C., Swoboda I., Balic N., et al. Exposure to a farming environment has allergen-specific protective effects on T(H)2-dependent isotype switching in response to common inhalants. J Allergy Clin Immunol 119 (2007) 351-358
23. Laupacis A., Sackkett D.L., and Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318 (1988) 1728-1733
24. Malling H.-J. Immunotherapy as an effective tool in allergy treatment. Allergy 53 (1998) 461-472
25. Khinchi M.S., Poulsen L.K., Carat F., André C., Hansen A.B., and Malling H.-J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59 (2004) 45-53
26. Eng P.A., Reinhold M., and Gnehm H.P.E. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 57 (2002) 306-312
27. Jacobsen L., Nuchel Petersen B., Wihl J.A., Lowenstein H., and Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts, IV: results from long-term (6-year) follow-up. Allergy 52 (1997) 914-920
28. Coffman R.L., Leb D.A., and Shrader B. Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med 170 (1989) 1039-1044
29. Borsutzky S., Cazac B.B., Roes J., and Guzman C.A. TGF-beta receptor signalling is critical for mucosal IgA responses. J Immunol 173 (2004) 3305-3309
30. Nouri-Aria K.T., Wachholz P.A., Francis J.N., Jacobson M.R., Walker S.M., Wilcock L.K., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172 (2004) 3252-3259
31. Jutel M., Jaeger L., Suck R., Meyer H., Fiebich H., and Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116 (2005) 608-613
32. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Wahley M.L., Khattignavong A.P., Lindblad R., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355 (2006) 1445-1455
33. Pree I., Reisinger J., Focke M., Vrtala S., Pauli G., van Hage M., et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 179 (2007) 5309-5316